INCY Company Profile and Key Details
NASDAQ : INCY
Incyte
$97.24
-0.58-0.59%
Open: 2:27 PM52.46
B-ESG ScoreESG Rating
Price Chart
Stock Price Today
Incyte Corporation (INCY) stock declined over -0.59%, trading at $97.24 on NASDAQ, down from the previous close of $97.82. The stock opened at $98.65, fluctuating between $96.58 and $98.70 in the recent session.
Stock Snapshot
97.82
Prev. Close
19.35B
Market Cap
96.58
Day Low
15.17
P/E Ratio
6.41
EPS (TTM)
2
Cash Flow per Share
98.65
Open
199.01M
Number of Shares
98.7
Day High
98.8%
Free Float in %
23.15
Book Value
482.61K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 17, 2026 | 96.60 | 97.94 | 95.63 | 97.82 | 1.53M |
| Apr 16, 2026 | 96.95 | 97.53 | 94.56 | 95.32 | 1.62M |
| Apr 14, 2026 | 95.76 | 97.90 | 95.76 | 97.69 | 1.37M |
| Apr 13, 2026 | 96.13 | 96.85 | 93.84 | 95.55 | 1.19M |
| Apr 10, 2026 | 97.53 | 97.57 | 95.41 | 96.07 | 1.15M |
| Apr 09, 2026 | 95.13 | 97.58 | 94.66 | 96.96 | 1.09M |
| Apr 08, 2026 | 95.39 | 95.98 | 93.50 | 95.89 | 1.15M |
| Apr 07, 2026 | 94.43 | 95.07 | 93.23 | 93.69 | 1.39M |
| Apr 06, 2026 | 94.96 | 96.14 | 94.00 | 94.86 | 997.89K |
| Apr 02, 2026 | 93.02 | 96.05 | 92.55 | 95.93 | 1.16M |
| Apr 01, 2026 | 94.65 | 95.56 | 93.80 | 94.30 | 1.48M |
| Mar 31, 2026 | 91.54 | 94.42 | 91.17 | 94.12 | 1.83M |
| Mar 30, 2026 | 91.13 | 91.69 | 90.08 | 90.33 | 1.53M |
| Mar 27, 2026 | 92.28 | 92.50 | 90.20 | 90.30 | 1.49M |
| Mar 25, 2026 | 91.00 | 93.83 | 91.00 | 92.23 | 1.04M |
| Mar 24, 2026 | 89.63 | 91.70 | 89.25 | 90.62 | 1.58M |
| Mar 23, 2026 | 91.16 | 92.33 | 90.00 | 90.45 | 1.42M |
| Mar 20, 2026 | 92.81 | 93.34 | 90.34 | 90.78 | 4.28M |
| Mar 19, 2026 | 91.88 | 93.57 | 91.72 | 92.95 | 1.33M |
| Mar 18, 2026 | 93.35 | 93.91 | 91.62 | 92.24 | 1.58M |
Contact Details
About Company
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Company Information
| Employees | 2617 |
| Beta | 0.86 |
| Sales or Revenue | $3.70B |
| 5Y Sales Change% | 0.865% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
20.69+2.50%
argenx SE$849.04REGN4.57+0.61%
Regeneron Pharmaceuticals, Inc.$750.57UTHR7.87+1.36%
United Therapeutics Corporation$588.38MDGL7.26+1.38%
Madrigal Pharmaceuticals, Inc.$532.02VRTX5.55+1.27%
Vertex Pharmaceuticals Incorporated$441.20PRAX22.11+6.90%
Praxis Precision Medicines, Inc.$342.50KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-10.47-3.27%
Alnylam Pharmaceuticals, Inc.$309.66KRYS10.15+3.84%
Krystal Biotech, Inc.$274.21ASND1.53+0.63%
Ascendis Pharma A/S$244.48Company Overview
Incyte Corporation (NASDAQ:INCY) closed at $97.18 USD, losing -$0.64 (-0.65%) from the previous close of $97.82. The stock is currently mid-range between its 52-week high and low $56.13 and $112.29. With a market capitalization of about $19.34 billion, Incyte Corporation is classified as a large-cap and shows market-like volatility (beta ~0.86). Key stats such as the average daily volume over the past year has been around 1.69 million shares, volume is running light vs its 52-week average. Headquartered in Wilmington, DE, Incyte Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO William J. Meury, the company employs approximately 2,617 people and listed since November 04, 1993. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
Technical Performance
Short-term trend indicators are mixed aligned (SMA20 -1.75%, SMA50 -2.1%, SMA200 14.83%). The stock’s 14-day RSI is 45.19 (neutral), while the ATR of 3.39 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -10.86% below its high and over 86.87% above its low. Average 10-day trading volume of 1.37 million shares is below the 3-month average of 1.70 million, indicating normal recent market interest.
Valuation Metrics
Incyte Corporation trades at a P/E ratio of 15.01, slightly below the S&P 500 average, with a price-to-sales ratio of 3.79 and a price-to-book ratio of 3.74 trading at moderately above to book value. The P/FCF stands at 14.37, also below market averages.
Dividend & Fair Value
Incyte Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $210.32. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Wall Street analysts project EPS growth of 12.95% annually over the next five years. The latest quarter delivered EPS of $2.11. The next quarter is forecast at $1.42. Next year's EPS is expected at $19.49. Analyst sentiment is neutral. Analyst rating data shows there are 11 Strong Buy ratings, 13 Buy ratings, 19 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $135.00 to $60.00. The high target offers 38.01% upside. The low target suggests -38.66% downside. The mean target is $101.66. This offers 3.93% upside. Incyte Corporation earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by 27.11%. The prior quarter beat by 12.95%. Over the last six quarters, Apple has recorded several small beats. These include -275.67% in July 30, 2024.
Shareholding & Insider Activity
Incyte Corporation has 195.28 million shares outstanding. The public float is 163.04 million shares, elevated short interest at 5.37% of float. This equals 7.42 million shares. The short ratio is 4.42 days. Institutional investors hold 107.45% of the float. Insiders own 1.87%. BAKER FELIX holds 2.93 million shares, BAKER BROS. ADVISORS LP has 2.93 million shares and Hoppenot Herve has 329.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 350.62 thousand shares across 19 transactions.
Financial & Profitability Overview
On valuation metrics, Incyte trades at a P/E of 15.01, P/S of 3.79 and P/B of 3.74. The current ratio is 3.32 and quick ratio is 3.25. Operationally, the company’s inventory turnover is 4.17 and cash conversion cycle is -21.54 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of 20.36.
Quarterly Financial Highlights
The company ended the quarter with $3.66B in cash and short-term investments, a total debt of $38.29M, and net debt of - $3.18B. Total assets were $6.78B, with equity of $5.19B. Financials further reflected stability, with operating cash flow of $496.49M, free cash flow of $449.00M, and capital expenditures of - $47.49M.
Price Forecast & Outlook
Our AI price prediction model suggests that Incyte Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.86%, with price expected at $100.62 by May 01, 2026, within a range of $98.94 to $102.18 3-Month Outlook: Projected rise of 31.14%, reaching $128.28 by July 16, 2026, with a range of $126.64 to $129.87. 1-Year Outlook: Projected gain of 10.88%, with price at $108.46 by April 16, 2027, within a range of $104.09 to $112.63.
Key Takeaways
Incyte Corporation (NASDAQ:INCY) shares are flat 3.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Incyte Corporation trading at a premium to the broader market with a P/E of 15.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $88.71, suggesting -9.31% downside. Our AI forecast model points to short-term strength (2.86% over two weeks), a medium-term rise (31.14% over three months), and a longer-term gain (10.88% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Incyte Corporation (INCY) stock price?
Incyte Corporation (NASDAQ: INCY) stock price is $97.24 in the last trading session. During the trading session, INCY stock reached the peak price of $98.70 while $96.58 was the lowest point it dropped to. The percentage change in INCY stock occurred in the recent session was -0.59% while the dollar amount for the price change in INCY stock was - $0.58.
INCY's industry and sector of operation?
The NASDAQ listed INCY is part of Biotechnology industry that operates in the broader Healthcare sector. Incyte Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of INCY?
Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.
Executive Vice President & GM of North America
Ms. Christiana Stamoulis MBA
Executive Vice President & Chief Financial Officer
Mr. Herve Hoppenot
Chief Executive Officer & Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.
Pres and Head of R&D
Ms. Christine Chiou
Head of Investor Relations
Dr. Dashyant Dhanak Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Thomas Tray
Vice President of Fin., Chief Accounting Officer & Controller
Ms. Pamela M. Murphy
Vice President of Investor Relations & Corporation Communications
Ms. Maria E. Pasquale J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Ms. Maria E. Pasquale
Executive Vice President, Gen. Counsel & Corporation Sec.
Dr. Steven H. Stein M.D.
Executive Vice President & Chief Medical Officer
Mr. Michael James Morrissey
Executive Vice President & Head of Global Technical Operations
Executive Vice President & GM of North America
Ms. Christiana Stamoulis MBA
Executive Vice President & Chief Financial Officer
Mr. Herve Hoppenot
Chief Executive Officer & Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.
Pres and Head of R&D
Ms. Christine Chiou
Head of Investor Relations
Dr. Dashyant Dhanak Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Thomas Tray
Vice President of Fin., Chief Accounting Officer & Controller
Ms. Pamela M. Murphy
Vice President of Investor Relations & Corporation Communications
Ms. Maria E. Pasquale J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Ms. Maria E. Pasquale
Executive Vice President, Gen. Counsel & Corporation Sec.
Dr. Steven H. Stein M.D.
Executive Vice President & Chief Medical Officer
Mr. Michael James Morrissey
Executive Vice President & Head of Global Technical Operations
How INCY did perform over past 52-week?
INCY's closing price is 74.27% higher than its 52-week low of $56.13 where as its distance from 52-week high of $112.29 is -12.89%.
How many employees does INCY have?
Number of INCY employees currently stands at 2,617.
Link for INCY official website?
Official Website of INCY is: https://www.incyte.com
How do I contact INCY?
INCY could be contacted at phone 302 498 6700 and can also be accessed through its website. INCY operates from 1801 Augustine Cut-Off, Wilmington, DE 19803, United States.
How many shares of INCY are traded daily?
INCY stock volume for the day was 482.61K shares. The average number of INCY shares traded daily for last 3 months was 1.69M.
What is the market cap of INCY currently?
The market value of INCY currently stands at $19.35B with its latest stock price at $97.24 and 199.01M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep